Amneal Pharmaceuticals Files Q2 2025 10-Q

Ticker: AMRX · Form: 10-Q · Filed: Aug 7, 2025 · CIK: 1723128

Sentiment: neutral

Topics: 10-Q, SEC filing, pharmaceuticals, compliance

Related Tickers: AMRX

TL;DR

**AMRX filed its 10-Q for Q2 2025, confirming compliance with SEC reporting.**

AI Summary

Amneal Pharmaceuticals, Inc. filed its quarterly report for the period ended June 30, 2025. The company is incorporated in Delaware and its Class A Common Stock trades under the symbol AMRX on The Nasdaq Stock Market LLC. This filing indicates Amneal has met its reporting requirements for the preceding 12 months and the past 90 days.

Why It Matters

This filing provides investors with an update on Amneal Pharmaceuticals' financial performance and operational status for the second quarter of 2025, crucial for investment decisions.

Risk Assessment

Risk Level: low — This is a standard quarterly filing confirming compliance and providing basic company information, not indicating any immediate financial distress or significant new risks.

Key Players & Entities

FAQ

What is the commission file number for Amneal Pharmaceuticals, Inc.?

The commission file number for Amneal Pharmaceuticals, Inc. is 001-38485.

On which exchange is Amneal Pharmaceuticals' Class A Common Stock traded?

Amneal Pharmaceuticals' Class A Common Stock is traded on The Nasdaq Stock Market LLC.

What is the par value of Amneal Pharmaceuticals' Class A Common Stock?

The par value of Amneal Pharmaceuticals' Class A Common Stock is $0.01 per share.

What is the principal executive office address for Amneal Pharmaceuticals, Inc.?

The principal executive office address for Amneal Pharmaceuticals, Inc. is 400 Crossing Boulevard, Bridgewater, NJ 08807.

Has Amneal Pharmaceuticals, Inc. filed all required reports for the preceding 12 months?

Yes, the filing indicates that Amneal Pharmaceuticals, Inc. has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months.

Filing Stats: 4,733 words · 19 min read · ~16 pages · Grade level 19.8 · Accepted 2025-08-07 16:10:36

Key Financial Figures

Filing Documents

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) 4 Consolidated Statements of Operations 4 Consolidated Statements of Comprehensive Income (Loss) 5 Consolidated Balance Sheets 6 Consolidated Statements of Cash Flows 7 Consolidated Statements of Changes in Stockholders' (Deficiency) Equity 9

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements 11 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 34 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 45 Item 4.

Controls and Procedures

Controls and Procedures 45

- OTHER INFORMATION

PART II - OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 46 Item 1A.

Risk Factors

Risk Factors 46 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 46 Item 3. Defaults Upon Senior Securities 46 Item 4. Mine Safety Disclosures 46 Item 5. Other Information 46 Item 6. Exhibits 47

Signatures

Signatures 48 1 Cautionary Note Regarding Forward-Looking Statements This Quarterly Report on Form 10-Q and other publicly available documents of Amneal Pharmaceuticals, Inc. contain "forward-looking statements" within the meaning of the safe harbor provisions of the United States ("U.S.") Private Securities Litigation Reform Act of 1995. Management and representatives of Amneal Pharmaceuticals, Inc. and its subsidiaries ("the Company", "we", "us", or "our") also may from time to time make forward-looking statements. Forward-looking statements do not relate strictly to historical or current facts and reflect management's assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as "plans," "expects," "will," "anticipates," "targets," "estimates," and other words of similar meaning in conjunction with, among other things: discussions of future operations; expected operating results and financial performance; impact of planned acquisitions and dispositions; our strategy for growth; product development; regulatory approvals; market position and expenditures. Because forward-looking statements are based on current beliefs, expectations and assumptions regarding future events, they are subject to uncertainties, risks and changes that are difficult to predict and many of which are outside of our control. Investors should realize that if underlying assumptions prove inaccurate, known or unknown risks or uncertainties materialize, or other factors or circumstances change, our actual results and financial condition could vary materially from expectations and projections expressed or implied in our forward-looking statements. Investors are therefore cautioned not to rely on these forward-looking statements. Summary of Material Risks Risks and uncertainties that make an investment in the Company speculative or risky or that could cause our actual results to differ materially from th

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial Statements (Unaudited)

Item 1. Financial Statements (Unaudited) Amneal Pharmaceuticals, Inc. Consolidated Statements of Operations (unaudited; in thousands, except per share amounts) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Net revenue $ 724,508 $ 701,780 $ 1,419,928 $ 1,360,971 Cost of goods sold 438,255 451,833 877,784 872,964 Gross profit 286,253 249,947 542,144 488,007 Selling, general and administrative 124,266 116,462 242,554 229,057 Research and development 47,964 36,054 88,004 75,352 Intellectual property legal development expenses 2,017 1,042 3,784 2,026 Restructuring and other charges 1,024 220 1,595 1,690 (Credit) charges related to legal matters, net ( 390 ) 699 ( 390 ) 95,058 Other operating (income) expense — — ( 5,122 ) 100 Operating income 111,372 95,470 211,719 84,724 Other (expense) income: Interest expense, net ( 65,101 ) ( 65,719 ) ( 122,040 ) ( 131,422 ) Foreign exchange gain (loss), net 8,256 ( 262 ) 12,503 ( 1,459 ) Increase in tax receivable agreement liability ( 4,420 ) ( 13,444 ) ( 15,107 ) ( 15,392 ) Other income, net 1,604 4,360 2,122 8,432 Total other expense, net ( 59,661 ) ( 75,065 ) ( 122,522 ) ( 139,841 ) Income (loss) before income taxes 51,711 20,405 89,197 ( 55,117 ) Provision for income taxes 16,101 3,618 28,969 9,774 Net income (loss) 35,610 16,787 60,228 ( 64,891 ) Less: Net income attributable to non-controlling interests ( 13,193 ) ( 10,793 ) ( 25,616 ) ( 20,758 ) Net income (loss) attributable to Amneal Pharmaceuticals, Inc. $ 22,417 $ 5,994 $ 34,612 $ ( 85,649 ) Net income (loss) per share attributable to Amneal Pharmaceuticals, Inc.'s Class A common stockholders: Basic $ 0.07 $ 0.02 $ 0.11 $ ( 0.28 ) Diluted $ 0.07 $ 0.02 $ 0.11 $ ( 0.28 ) Weighted-average common shares outstanding: Basic 313,739 309,117 312,404 308,198 Diluted 322,363 318,957 323,171 308,198 The accompanying notes are an integral part of these consolidated financial statements. 4 Amneal Pharmaceutica

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements (unaudited) 1. Summary of Significant Accounting Policies Basis of Presentation The interim unaudited consolidated financial statements have been prepared in accordance with the requirements of the U.S. Securities and Exchange Commission and U.S. generally accepted accounting principles ("U.S. GAAP") for interim reporting. These financial statements include all adjustments that in the opinion of management are necessary for a fair presentation of the financial position, results of operations, and cash flows of Amneal Pharmaceuticals, Inc. (the "Company") for the periods presented. However, these financial statements do not include all information and accompanying notes required for annual financial statements prepared in accordance with U.S. GAAP. The interim unaudited consolidated financial statements should be read in conjunction with the audited annual financial statements included in the Company's 2024 Annual Report on Form 10-K. Use of Estimates The preparation of financial statements requires the Company's management to make estimates and assumptions that affect the reported financial position at the date of the financial statements and the reported results of operations during the reporting period. Such estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses, and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. The following are some, but not all, of such estimates: the determination of chargebacks, sales returns, rebates, valuation of intangible and other assets acquired in business combinations, allowances for accounts receivable, accrued liabilities, liabilities for legal matters, contingent liabilities, stock-based compensation, valuation of inventory balances, the determination of useful lives for product rights and the assessment of expected cash flows used in evaluating goodwill and other long-liv

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing